Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓ 💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives Grateful to work with a global amazing team 🙏 Link to the Review:👇 doi.org/10.1016/j.ctrv…

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect cancerletter.com/podcastc/202...

It’s official!!🌟 The @myESMO advanced course on early-stage #NSCLC will be held in Athens 🇬🇷 🏛️ 29-30 April 2025 with a deep dive in try strategies! Excited to co-chair with 2 amazing ladies @peters_solange and @ElinardouHelena and a stellar European faculty! Apply here: 👇 esmo.org/meeting-calend…

JOIN US at #APCCCDiagnostics25 🇨🇭in Lugano A HYBRID Meeting (In Person & Live) Switzerland February 27-28, 2025 REGISTER: apccc.org/apccc-diagno... ONLINE REGISTRATION FOR LMIC's FREE @silkegillessen.bsky.social @aureliusomlin.bsky.social @barbaramelao.bsky.social @drnataliagandur.bsky.social

Wishing you a year filled with strength, hope, and the knowledge that you are not alone in the fight against cancer. Happy New Year 2025!

Happy new year from Majestic #Edinburgh!!! May 2025 fill your hearts with joy, happiness, creativity and love!!! 🏴󠁧󠁢󠁳󠁣󠁴󠁿✨💫

Ivonescimab, a novel bispecific Ab targeting PD-1 and VEGF, outperformed gold std pembro in a head to head comparison. It may unlock IO options for new patient pops, including EGFR+ post-TKI and SqNSCLC, plus other tumor types. #LCSM 👁️🫁 www.onclive.com/view/the-nov...

🌟 2024 has been an amazing year for #lungcancer , mainly due to biotechnology breakthroughs leading to pivotal new drugs entering clinical arena. In the thread below you can see (in reverse order) ➡️10 EXCITING COMPOUNDS⬅️ that, IMO will shape innovation in 2025: #LCSM #some

Dear Colleagues, Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨 @drchoueiri.bsky.social @icromeattini.bsky.social @hoperugo.bsky.social @yukselurun.bsky.social @aftimosp.bsky.social @jrgralow.bsky.social @elisabettabonzano.bsky.social

#ESMOImmuno24 Proffered paper🔥 Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social - no PFS/OS benefit - g3+TRAE 57%, 54%, 49% - concerning pneumonitis signal Concurrent RT+IO - going going gone @oncoalert.bsky.social #LCSM #Medsky #Oncsky

Η ανάσα μας είναι ότι πολυτιμότερο έχουμε, είναι η ίδια μας η ζωή. Οποιοσδήποτε με πνεύμονες μπορεί να νοσήσει από καρκίνο πνεύμονα. Ακούστε σε αυτό το σύντομο βίντεο με την εξαιρετική συνάδελφο @ElinardouHelena πώς μπορούμε να θωρακιστούμε!! #καρκινοσπνευμονα #stopsmoking @HeSMO_X @fairlifelcc

Coming back from the 10th edition of #SACII in Larissa-Greece and it felt like home! Incredible hospitality, engaging IO talks, and the joy of reconnecting with friends like @drgreeklungcancer.bsky.social while making new ones 🎯 Always wearing my #JITC Jeffrey Weber memorial bow-tie pin🎗️

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer www.nature.com/articles/s41...

Honoured to be included among the 100 Top Xfluencers in #lungcancer in 2024 and a huge responsibility to contribute to spreading scientific knowledge precisely and shaping scientific innovation to a more dynamic 2025!!! #some #lcsm @oncodaily @OncoAlert @VJOncology @IASLC @HeSMO_X @fairlifelcc

4th Annual @fairlifelcc: A Celebration of Hope & Commitment! 🌟 📊 3,998 participants (online & in-person) 🎤 65 speakers & panelists 🌟 20 endorsements 🤝 11 supporters Together, we’re making change happen. #Thankyou all! 💙 #FairLifeLCC #LungCancerAwareness #TogetherForChange

A strategic position statement in @Annals_Oncology on the main actions to boost #lungcancer research and innovation: ✅ Pragmatic trials ✅ Ensure inclusivity and diversity ✅ NGS in resectable #NSCLC ✅ Exploit resistance mech ✅Focus on novel Tox bit.ly/4ga8LlC #LCSM #some @iaslc.bsky.social

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in @natrevclinoncol.bsky.social highlighting: ➡️Strategies to improve on 1L 3rd Gen TKI mono therapy ➡️ Ways to tackle resistance post-Osi ➡️Perioperative landscape @LeXiuning @danieltanmd @RamalingamMD @IASLC #LCSM #some

Join us virtually on December 8th for a festive 🎄end-of- year recap of the NSCLC landscape, organized @iaslc.bsky.social and focusing on Eastern Europe and Baltic states. Happy to join a multi-disciplinary panel and grateful to @christianrolfo.bsky.social and Alona Zer for the support #some #lcsm

🧬 “Real-world Dabrafenib-Trametinib (D-T) for BRAF V600E-mutated NSCLC” The IFCT-2004 BLaDE study confirms: • Significant efficacy in both pretreated & untreated patients • 12-month OS: 67.4% • Median PFS: 10.4 (2L+), 18.2 mths (1L) 🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯

Unfortunately, this may mean continually reducing interest in TIGIT as a target! endpts.com/roches-tigit...

Interesting paper identifies 3 subgrps of pulm carcinoid @jtoonline.bsky.social - 3 subtypes by mRNA & 🇳🇱registry by IHC - A1=OTP+/ASCL1+/HNF1A (53%) - A2=OTP+/ASCL1/HNF1A+ (38%) - B=OTP/ASCL1/HNF1A+ (9%) Nxt step- assist tx selectn? www.jto.org/article/S155... #Oncsky #LCSM @oncoalert.bsky.social

🧵 Our grandmas were onto something when they told us to have some tea when we were sick. Cool paper showing several Omicron-era #SARSCoV2 variants effectively inactivated by green tea, Matcha, & black tea, mediated by EGCG and TFDG: www.nature.com/articles/s41... #MedSky #IDSky #MedEd #COVID19 /1

<3wks to go! Excited to discuss how the data from #SABCS24 will change/reinforce our clinical practice at the Advancements in Oncology! In Person, 📆 Date: Dec 11, 2024 ⏰Time:7-9PM Register here: bit.ly/aiosabcs24 #OncSky #MedSky #bcsm #AdvInOnc24 @drsgraff.bsky.social @drgattimays.bsky.social

FDA issued a warning letter to Tom’s of Maine about microbial contaminations of toothpaste & other sig concerns. I texted a relative who uses it to let them know, & they sent back a pic showing me they just finished a tube. Zoom in to see the words. 🤦🏻‍♀️ #IDSky #Irony www.fda.gov/inspections-...

Space grown human brain organoids, H/T: @jung-sillah.bsky.social

"The Value of Offering #Oncofertility Counseling in Young Patients With Newly Diagnosed Cancer Is Unquestionable" 🫳🎤The name says it all. 🙏 Authors and #JCOOP journal #ASCO #AYACsm #AYAc #oncSky #canSky ascopubs.org/doi/10.1200/...

I know many other have done these but I’ve collected almost 100 people and my personal list is hard to share. go.bsky.app/2mRM9TD

Study: Most people at high risk for lung cancer have not discussed screening, or been heard of the test @jamacurrent.bsky.social jamanetwork.com/journals/jam...

Honored and excited to attend the #10thSACII symposium in Larissa🇬🇷! I’ll be speaking right after my friend @drgreeklungcancer.bsky.social but I swear, it’s pure coincidence! Neither of us knew the other was participating until now! 😄 Super interesting program though 👇👇 sacii-greece.org

OA RoundUp🚨Nov 15-21 youtu.be/BDg6UDh2WvE @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @agerikssonmd.bsky.social @fernandoonco.bsky.social @icromeattini.bsky.social @drnataliagandur.bsky.social @biagioricciutimd.bsky.social @yukselurun.bsky.social

Vote in the ASCO Election - now through December 3 Help ASCO choose the Society’s future leaders, plus earn a point toward FASCO designation for voting! society.asco.org/about-asco/a...

Final survival results from phase II study of lorlatinib in #ALK NSCLC @jtoonline.bsky.social. In treatment naive (n=30), 5y OS 76%. Post 2nd gen ALK TKI ± chemo (n=28), 5y OS 45%, median OS 37.4m. Post ≥2 ALK TKIs ± chemo (n=111), 5y OS 23%, median OS 19.2m. #LCSM www.jto.org/article/S155...

I made a #LCSM list, small but growing! Not sure how to make it public? bsky.app/profile/did:... @jackwestmd.bsky.social @stephenvliu.bsky.social @pateloncology.bsky.social @tlblase.bsky.social @devikadasmd.bsky.social @jia-luo.bsky.social @garthnicholas.bsky.social

Join the Lung 🫁 Cancer Hub to learn everything about Lung Cancer Research and Practice!! Link : 👇 go.bsky.app/DGxuxHC Become a member of the hub, post your news/opinions/ideas and keep real-time update on #LCSM !!

If you’ve been accumulating follows you may be getting overwhelmed by your main feed. Make LISTS and add various accounts to them, then Pin them to your home. You can then check out each feed one at a time and get more focused info. I have LCSM, general med-onc, Steelers, and News for example.

Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social #some #lungcancer

Every avenue explored in lung cancer research brings new insights to get closer to breakthroughs It's why Dr Merajver believes in exploring so many angles. She says "From new and repurposed drugs, new models, personalized studies and more, research is about improving lives.”

Loving the 🦋 activity I wake up to every morning Meanwhile my X is all quiet 🤔